Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 561-565

  Malik, Imtiaz A ^a   Mehboobali, Naseema ^b   Iqbal, M Perwaiz ^b  

^a National Cancer Institute   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Glutathione; GSH; IFEX ifosfamide; PBL peripheral blood lymphocytes

Indexed keywords

ALKYLATING AGENT; CISPLATIN; CLEMASTINE; DEXAMETHASONE; GLUTATHIONE; IFOSFAMIDE; MESNA; METOCLOPRAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; GLUTATHIONE; HUMANS; IFOSFAMIDE; LYMPHOCYTES; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031032439     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050616     Document Type: Article

References (37)

1. Andrews PA, Murphy MP, Howell SB (1985) Differential potentiation of alkyating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion Cancer Res 45:6250
2. Arrick BA, Nathan CF (1984) Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 44:4224
3. Averette HE, Donato DM (1990) Ovarian carcinoma: advances in diagnosis, staging and treatment. Cancer 65:703
4. Brade W, Seeber S, Herdrich K (1986) Experimental and clinical activity of ifosfamide and cyclophosphamide. Cancer Chemother Pharmacol 18 [Suppl 2]: S1
5. Canada A, Herman L, Kidd K, Robertson C, Trump D (1993) Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line. Cancer Chemother Pharmacol 32:73
6. Chabner BA, Fine RL, Allegra CJ, et al. (1984) Cancer chemotherapy: progress and expectations. Cancer 54:2599
7. Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428
8. Edwards PG (1988) Evidence that glutathione may determine the differential cell-cycle phase toxicity of a platinum (IV) anti-tumor agent. J Natl Cancer Inst 80:734
9. Eichholtz-Wirth H, Reidel G, Hietel B (1993) Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content. Br J Cancer 67:1001
10. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF (1984) Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44:5427
11. Gurtoo HL, Hipkens JH, Sharma CD (1981) Role of glutathione in the metabolism dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res 41:3584
12. Hamilton TC, Winkler C, Louie K, Batist G, Behrens B, Ozols RF (1985) Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by glutathione depletion. Biochem Pharmacol 34:2583
13. Hamilton TC, Lai GM, Rothenberg ML, Fojo A, Young RC, Ozols RF (1989) Mechanisms of resistance to alkylating agents and cisplatin. In: Ozols RF (ed) Cancer treatment and research: drug resistance. Martinis Nijhoff, Boston, p 151
14. Hospers GAP, Mulder NH, De Jon B, De Ley L, Uges DRA, Fichtinger-Schepmann AMJ, Scheper RT, DeVries EGE (1988) Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res 48:6803
15. Iqbal MP, Malik IA, Mehboobali N, Waqar MA (1993) A spectrophotometric method for glutathione levels in normal and tumor cells. Proceedings, 5th national chemistry conference, Quaid-i-Azam University, Islamabad, Pakistan
16. Issels RD, Nagele A (1989) Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res 49:2082
17. Issels RD, Nagele A, Eckert KG, et al (1988) Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol 37:881
18. Issels RD, Meier TH, Muller E, Multhoff G, Wilmanns W (1993) Ifosfamide induced stress response in human lymphocytes. Mol Aspects Med 14:281
19. Klaassen U, Harstrick A, Vanhoefer U, Schleucher N, Stahl M, Seeber S, Wilke H (1994) Activity and schedule-dependent interactions of taxol, ifosfamide and etoposide in cisplatin sensitive and refractory human ovarian carcinoma cell lines as a basis for second line protocols (abstract 4917). Ann Oncol 5 [Suppl 8]:98
20. Liebman JE, Hahn SM, Cook JA, Lipshultz C, Mitchell JB, Kaufman DC (1993) Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 53:2066
21. Lind MJ, McGowan AT, Hadfield JA, Thatcher N, Crowther D, Fox BW (1989) The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 38:1835
22. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Young RC, Ozols RF (1985) Radiation survival parameters of antineoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110
23. Masuda H, Ozols RF, Lai, GM, et al. (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48:5713
24. Meier T, Allenbacher A, Mueller E, Multhoff G, Botzler C, Weisnet M, Issels R (1994) Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anticancer Drugs 5:403
25. Meister A (1983) Selective modification of glutathione metabolism. Science 220:472
26. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
27. Ozols RF, Louie KG, Plowman J, et al. (1987) Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36:147
28. Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC (1990) The role of glutathione in drug resistance. Cancer Treat Rev 17:45
29. Saito G, Yoshimura S, Iwasaki K, Kuroshima Y, Moriuchi T (1994) Suppression of plasma glutathione peroxidase activity by ifosfamide. Asia Oceania J Obstet Gynaecol 20:441
30. Slater AJ, Green JA (1989) Phase II study of cisplatin and ifosfamide in alkylating agent resistant ovarian cancer. Gynaecol Oncol 32:233
31. Somfai-Relle S, Suzukake K, Vistica BP, Vistica DT (1984) Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol 33:485
32. Stofer-Vogel B, Cerny T, Kupfer A, Junker E, Lauterburg BH (1993) Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br J Cancer 68:590
33. Sutton GP, Blessing JA, Homesley HD, et al (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7:1672
34. Suzukake K, Petro BJ, Vistica DT (1982) Reduction in glutathione content of L-PAM-resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 31:121
35. Suzukake K, Petro BJ, Vistica DT (1983) Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 32:165
36. Tietze K (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 27:502
37. Zalupski M, Baker LH (1988) Review: ifosfamide. J Natl Cancer Inst 8:555